Human milk oligosaccharides and its acid hydrolysate LNT2 show immunomodulatory effects via TLRs in a dose and structure-dependent way by Cheng, Lianghui et al.
  
 University of Groningen
Human milk oligosaccharides and its acid hydrolysate LNT2 show immunomodulatory effects
via TLRs in a dose and structure-dependent way
Cheng, Lianghui; Kiewiet, Mensiena B. G.; Groeneveld, Andre; Nauta, Arjen; de Vos, Paul
Published in:
Journal of Functional Foods
DOI:
10.1016/j.jff.2019.05.023
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Cheng, L., Kiewiet, M. B. G., Groeneveld, A., Nauta, A., & de Vos, P. (2019). Human milk oligosaccharides
and its acid hydrolysate LNT2 show immunomodulatory effects via TLRs in a dose and structure-dependent
way. Journal of Functional Foods, 59, 174-184. https://doi.org/10.1016/j.jff.2019.05.023
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
Contents lists available at ScienceDirect
Journal of Functional Foods
journal homepage: www.elsevier.com/locate/jff
Human milk oligosaccharides and its acid hydrolysate LNT2 show
immunomodulatory effects via TLRs in a dose and structure-dependent way
Lianghui Chenga,⁎, Mensiena B.G. Kiewieta, Andre Groeneveldb, Arjen Nautab, Paul de Vosa
a Immunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen,
Hanzeplein 1, 9700 RB Groningen, the Netherlands
b FrieslandCampina, Stationsplein 4, 3818 LE Amersfoort, the Netherlands






A B S T R A C T
Human milk oligosaccharides (HMOs) have beneficial immune effects but the mechanisms of action are not well-
understood. Here we study Toll-like receptor (TLR) signaling of the HMOs 2′-FL, 3-FL, 6′-SL, LNT2, and LNnT
and their effect on cytokine production in human macrophages. 3-FL activated TLR2 and LNT2 activated all TLRs
in a dose-dependent way. In an inhibition assay, 2′-FL, 6′-SL, and LNnT inhibited TLR5 and 7, while 3-FL in-
hibited TLR5, 7, and 8. 6′-SL showed a synergistic effect on ssRNA40-induced TLR8 activation. In addition, we
measured HMO-induced cytokine production in THP1 macrophages. IL-10 and TNFα were induced by LNT2, and
the effects were NF-κB dependent, while the other HMOs had minor effects. The potent effects of LNT2 might be
explained by the unique N-acetylglucosamine end that binds to leucine-rich repeats on TLRs. Our data suggest
that the effects of HMOs on TLR signaling and immunomodulation of macrophages are HMO-structure depen-
dent.
1. Introduction
Breastfeeding is the golden standard for infant feeding in the first
6months of life (Walker, 2010). It provides the necessary nutrition to
the infant but also supports the immune defense in the phase of the
immaturity of the immune system of the neonates. It has been shown
for example that breastfed infants have a lower risk of infection and
inflammation than formula-fed babies (Klement, Cohen, Boxman,
Joseph, & Reif, 2004; Ladomenou, Moschandreas, Kafatos, Tselentis, &
Galanakis, 2010). Human milk oligosaccharides (HMOs) have been
shown to be one of the responsible molecules in human milk for the
immune supporting effects in neonates (Buescher, 2001).
HMOs are non-digestible carbohydrates comprising a family of more
than 200 different oligosaccharides with highly diverse structures
(Bode, 2012; Kunz, Rudloff, Baie, Klein, & St, 2000). HMOs can be
found in mother’s milk in concentrations varying between 5 and 20mg/
mL (Bode, 2012; Petherick, 2010), depending on the stage of lactation
and may provide a variety of health-promoting effects (Bode, 2012;
Kunz et al., 2000; Smilowitz, Lebrilla, Mills, German, & Freeman,
2014). These health effects vary from promoting gut microbiota de-
velopment (Asakuma et al., 2011), reducing pathogenic infections by
acting as anti-adhesive molecule (Morrow et al., 2004), supporting
brain development and cognition (Belfort, 2018; Wang, 2009), but also
playing a role in supporting development of the mucosal and systemic
immune system (Ayechu-Muruzabal et al., 2018; He, Liu, Leone, &
Newburg, 2014). Which HMO is responsible for which health effect is
not completely known but subject of intensive research efforts.
HMOs have been shown to stimulate immune function in different
ways (Bode et al., 2004; Lane, O’Callaghan, Carrington, & Hickey,
2013; Velupillai & Harn, 1994; Vos et al., 2007). For example, colos-
trum derived HMOs attenuated pathogen-associated molecular pattern
(PAMP) induced acute phase inflammatory cytokine production in in-
tact immature human intestinal mucosa and the immature intestinal
epithelial cell line H4 (He et al., 2014). Simultaneously, it stimulated
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tissue repair and homeostasis (He et al., 2014). The HMO 2′-fuco-
syllactose (2′-FL) attenuated interleukin (IL)-8 production which was
induced by lipopolysaccharide (LPS) derived from type 1 pili pathogens
(He, Liu, et al., 2016). Disialyllacto-N-tetraose (DSLNT) also have been
identified as immunemodulating and immune attenuating HMO. It
suppresses necrotising enterocolitis-like inflammation in neonatal rats
(Jantscher-Krenn et al., 2012). However, there are also HMOs that have
immune stimulating properties. The HMO 3′-sialyllactose (3′-SL), for
example, showed immune stimulating characteristics by stimulating
mesenteric lymph node CD11c+ dendritic cells to increase the pro-
duction of IFN-γ, TNF-α, IL-12, and TGF-β1 that induced Th1 and Th17
cell frequencies (Kurakevich, Hennet, Hausmann, Rogler, & Borsig,
2013). Also, the HMO lacto-N-fucopentaose III (LNFP III) was found to
have immunomodulatory activaties that induced strong Th2 responses
and promoted dendritic cell 2 (DC2) maturation (Thomas et al., 2014).
Some studies suggest that immune effects by HMOs can be induced
via Toll-like receptors (TLRs) (He, Lawlor, & Newburg, 2016). TLRs are
a family of pattern recognition receptors (PRRs) that play an important
role in immune signaling, and TLR signaling is central to innate im-
munity (He, Lawlor, et al., 2016; Kawai & Akira, 2010). TLRs are ex-
pressed by many cell types, including by most immune cells and epi-
thelial cells (Abreu, 2010; Kawai & Akira, 2010). Their ligands are
PAMPs but also multiple dietary molecules can be recognized by TLRs
(Figueroa-Lozano, Valk-Weeber, van Leeuwen, Dijkhuizen, & de Vos,
2018; Kiewiet et al., 2017; Sahasrabudhe et al., 2018; Vogt et al., 2013).
Activation of TLRs might lead to immune signaling through NF-κB re-
sulting in the modulation of cytokine release (Kawai & Akira, 2010;
Medzhitov, 2001). A study using a human colonic cell line (HT-29)
showed that lacto-N-fucopentaose I (LNFP I) increased the gene ex-
pression of TLR4, while 3′-sialyllactose (3′-SL), 6′-sialyllactose (6′-SL)
or 6′-galactosyllactose (6′-GL) enhanced both TLR2 and TLR4 expres-
sion (Asakuma et al., 2010). This study also showed that TLR4 not only
mediates the effect of LNFP III on promoting DC2 maturation (Thomas
et al., 2014), but also the DC response induced by 3′-SL (Kurakevich
et al., 2013). A study on H4 intestinal cells showed that 3′-, 4-, and 6′-
GL attenuated the polyinosinic:polycytidylic acid induced in-
flammatory response through TLR3 (He et al., 2014).
Although some studies have demonstrated that HMOs have the
ability to modulate immunity via TLR signaling, the relative effects of
individual oligosaccharides on TLRs are still not well-understood.
HMOs are also subject to modifications during passage through the
gastrointestinal tract. Research shows that acidic HMO fractions among
are hydrolyzed at low pH (Gnoth, Kunz, Kinne-Saffran, & Rudloff,
2000). This may lead to production of products such as lacto-N-triose
(LNT2), which is the acid hydrolysates of the tetra and higher HMOs
such as lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) (Bidart,
Rodríguez-Díaz, & Yebra, 2016; Deo & Park, 2006; Gnoth et al., 2000).
Therefore, in the present study, we compared the effects of different
HMOs (2′-FL, 3-FL, 6′-SL and LNnT) and its acid hydrolysate LNT2 on
TLR signaling. The activation and inhibition effects on TLR 2, 3, 4, 5, 7,
8, and 9 and the immunomodulatory effects on human THP1 macro-
phages were assessed.
2. Materials and methods
2.1. HMOs
In the present study, five different human milk oligosaccharides
(HMOs) 2′-FL (provided by FrieslandCampina Domo, Amersfoort, the
Netherlands), 3-FL, 6′-SL, LNT2, and LNnT (provided by Glycosyn LLC,
Woburn, MA, USA) were tested. An overview of the structure and
components of the selected HMOs are shown in Table 1. All samples
were tested after 0.2 µm filtration for endotoxins by using Limulus
Amebocyte Lysate (LAL) Chromogenic Endotoxin Quantitation Kit
(Pierce™ LAL Chromogenic Endotoxin Quantitation Kit, Thermo Sci-
entific, Breda, The Netherlands) according to the manufacturer’s
instructions (Fig. S1).
2.2. Cell culture of THP1 and HEK reporter cell lines
To study the effects of HMOs on TLR signaling, the human acute
monocytic leukemia reporter cell line (THP1) (InvivoGen, Toulouse,
France) and 7 human embryonic kidney (HEK) reporter cell lines (HEK-
Blue™-hTLRX) (InvivoGen, Toulouse, France) were used. The THP1
cells line (THP1-XBlue™-MD2-CD14) expresses TLRs endogenously and
carries an insert for MD2 and CD14 which boosts TLR signaling. HEK-
Blue reporter cell lines express a construct for individual TLRs (TLR2, 3,
4, 5, 7, 8, and 9). Both the THP1 and HEK reporter cell lines also
contain a Secreted Embryonic Alkaline Phosphatase (SEAP) construct,
which is coupled to the nuclear factor κB/Activating protein-1 (NF-κB/
AP-1) promoter. In all these cells, activation of TLRs leads the expres-
sion of the SEAP gene. The SEAP secretion in the medium can, there-
fore, be assessed as a measure for the induced TLR activation (Chanput,
Mes, & Wichers, 2014).
THP1 cells were passaged twice a week by inoculating 5× 105 cells.
Cells were cultured in RPMI 1640 medium (Gibco, Life Technologies,
Bleiswijk, The Netherlands), containing 10% heat-inactivated FBS
(Fetal Bovine Serum, HyClone, Thermo Scientific, Breda, The
Netherlands), 2 mM L-glutamine, 1.5 g/L sodium bicarbonate (Boom
B.V. Meppel, The Netherlands), 4.5 g/L glucose, 10mM HEPES, 1.0 mM
sodium pyruvate, 100mg/mL Normocin™ (Invivogen, Toulouse,
France), and 50 U/mL and 50 μg/mL Penicillin/Streptomycin. All ad-
ditives were purchased from Sigma Aldrich (Zwijndrecht) unless in-
dicated otherwise.
HEK-Blue cells were maintained in Dulbecco’s modified eagle’s
medium (DMEM) (Gibco, Life Technologies, Bleiswijk, The
Netherlands) with 10% heat-inactivated FBS, 2mM L-glutamine, 4.5 g/
L glucose, 50 U/mL and 50mg/mL penicillin/streptomycin, and
100mg/mL Normocin. HEK cells were grown to approximately 80%
confluency.
All the reporter cell lines were passaged three times before they
were maintained in their respective selection medium according to the
manufacturer’s protocol.
2.3. THP1 reporter cell stimulation and Quanti-Blue assay
THP1 cells were centrifuged for 5min at 300g, and cells were re-
suspended in culture medium, using the cell density per well as in-
dicated in Table 2. Next, cells were seeded in a flat bottom 96 wells
plate (100 μL). Cells were preincubated with or without 50 µM MyD88
inhibitor Pepinh-MYD (InvivoGen, Toulouse, France) for 6 h (37 °C,
95% oxygen, 5% CO2), after which they were stimulated for 24 h with
Table 1
Overview of the structure of selected HMOs and its acid hydrolysate LNT2.
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0.5, 1, and 2mg/mL HMOs or a relevant ligand as a positive control
(Table 2). Unstimulated cells were used as negative control. To detect
the TLR activation in cells, after 24 h the culture supernatant was mixed
with Quanti-Blue detection medium in a ratio of 1:10 in a new plate and
incubated for 1 h at 37 °C and 5% CO2. Absorbance (650 nm) was
measured using a Benchmark Plus Microplate Reader using Microplate
Manager version 5.2.1 for data acquisition. The data for each sample
was plotted as the fold-change compared to the negative control, which
was well with unstimulated cells. The assays were performed with three
technical replications and each experiment was repeated five times.
2.4. HEK-Blue reporter cell stimulation and Quanti-Blue assay
To assess the activation of individual TLR signaling, HEK-Blue cells
were detached from the bottom flask by tapping the flask, after which
the cells were centrifuged and resuspended according to the manu-
facturer’s protocol (Table 2). After that, cells were seeded at different
cell densities (Table 2) in a flat bottom 96 wells plate at 100 µL per well.
The cells were incubated for 24 h (37˚C, 95% oxygen, 5% CO2) with 0.5,
1, and 2mg/mL HMOs, LNT2 was added to the culture medium after
sterile filtration. For each HEK cell line, a corresponding TLR agonist
was used as a positive control (Table 2), and the medium was used as a
negative control. To exclude possible effects of endotoxin on TLR4 ac-
tivation, 100 µg/mL polymyxin B was added to capture any LPS present
in the 2′-FL, 6′-SL, and LNT2 solutions, as LAL assay detected endotoxin
in these three HMOs. After 24 h of incubation, the Quanti-Blue assay
was conducted as described above. Data for each sample were plotted
as the fold-change compared to the negative control, which was un-
stimulated cells. The negative controls were set at 1.
Besides activating TLRs, HMOs might also inhibit ligand-induced
TLR activation (Sahasrabudhe, Schols, Faas, & de Vos, 2016). Inhibition
of the individual TLR was studied by comparing the NF-κB activation of
respective TLRs agonists (Table 2) with the cells treated with TLR
agonist and sample together. To assess inhibition of the TLR signaling
by different concentrations of HMOs, HEK cells were resuspended and
seeded in the same way as described above for the activation assays.
Then, cells were stimulated with the appropriate TLR ligand (Table 2),
together with 0.5, 1, and 2mg/mL HMOs for 24 h (37 °C, 95% oxygen,
5% CO2). The TLR ligand alone served as a positive control. After in-
cubation, SEAP activity was performed in the same way as described
above (Chanput et al., 2014). Data for each sample were plotted as the
fold-change compared to the positive control. The positive controls
were set at 1.
The activation and inhibition assays were performed with three
technical replicates and each experiment was repeated five times.
2.5. THP1 monocytes cell culture
THP1 monocytes (ATCC TIB‐202, Rockville, MD, USA), derived
from an acute monocytic leukemia, were maintained in RPMI 1640
medium (Lonza, Verviers, Belgium). Cell culture medium was supple-
mented with 10% heat-inactivated FBS, 2mM L-glutamine (Lonza,
Verviers, Belgium), 1mM sodium pyruvate (Lonza, Verviers, Belgium),
0.05mM 2-mercaptoethanol (Scharlau, Barcelona, Spain), 60 µg/mL
gentamicin sulfate (Lonza, Verviers, Belgium), 2.2 µg/ml amphotericin
B solubilized (Sigma-Aldrich, St. Louis, MO USA). Cells were incubated
at 37 °C with 5% CO2. The medium was changed every 2 to 3 days, and
cells were subcultured when the cell concentration reached
8×105 cells/mL.
2.6. THP1 monocytes differentiation to macrophages and stimulation
THP1 monocytes were differentiated into THP1 macrophages as
previously described (Ren et al., 2016). Briefly, THP1 monocytes
(5×105 cells/well, in 0.5mL) were differentiated for 48 h with
100 ng/mL Phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) in a
48 wells plate (Corning, New York, USA). After that, PMA was removed
and cells were washed twice with fresh culture medium and cultured
for another 24 h. Next, the culture medium was discarded and cells
were incubated with either 10 µM of the NF-κB inhibitor celastrol (In-
vivoGen, Toulouse, France) or culture medium for 30min. Subse-
quently, fresh medium containing 0.5, 1, and 2mg/mL HMOs samples
or 1 µg/mL LPS (positive control) were added to the cells. Unstimulated
cells served as negative control. After 24 h of incubation, the secretion
of a proinflammatory (TNFα) and anti-inflammatory cytokine (IL-10)
was measured in the supernatant by ELISA (R&D SYSTEM, Minneapolis,
MN, USA) according to the manufacturer’s protocol.
The stimulation assays were performed with two technical re-
plicates and each experiment was repeated five times.
2.7. Statistical analysis
The results were analyzed using GraphPad Prism. The distribution
of the data was tested by using the Kolmogorov-Smirnov test. Values
are expressed as mean ± standard deviation (SD). Statistical compar-
isons of parametric distributed data were performed using unpaired t-
tests, one-way ANOVA with Dunn’s multiple comparison tests or two-
way ANOVA for group analysis. Non-parametric distributed data was
assessed using the Kruskal-Wallis test followed by the Dunn’s test.
p < 0.05 was considered as statistically significant (*p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001).
Table 2
Cell densities and agonists used in the different reporter cell line assays.
Cell line Cell density (cell/mL) Agonist (positive control) Agonist concentration
THP1-MD2-CD14 5×105 LPS-EK
Standard lipopolysaccharide from E. coli K12
10 ng/mL
HEK-Blue human TLR2 2.8× 105 FSL-1
lipopeptide
10 ng/mL
HEK-Blue human TLR3 2.8× 105 Poly (I:C) HMW
Poly (I:C) High Molecular Weight
5 µg/mL
HEK-Blue human TLR4 1.4× 105 LPS-EK
Standard lipopolysaccharide from E. coli K12
10 ng/mL
HEK-Blue human TLR5 1.4× 105 RecFLA-ST
Recombinant flagellin from Salmonella typhimurium
10 ng/mL
HEK-Blue human TLR7 2.2× 105 CL264
Adenine analog
5 µg/mL
HEK-Blue human TLR8 2.2× 105 ssRNA40/LyoVec
Single stranded RNA
5 µg/mL
HEK-Blue human TLR9 4.5× 105 ODN 2006
Class B CpG oligonucleotide
0.25 µM
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3. Results
3.1. Induction of TLR and MyD88-dependent activation in THP1-MD2-
CD14 cells by 3-FL and LNT2
To determine whether HMOs induce TLR signaling through the
MyD88 pathway, first THP1-MD2-CD14 cells were stimulated with the
different HMOs. By comparing the data with stimulated THP1-MD2-
CD14 cells in which MyD88 signaling is blocked we determined TLR
dependency.
HMOs and its acid hydrolysate LNT2 were tested at a concentration
of 0.5, 1, and 2mg/mL. As shown in Fig. 1A, 2′-FL had no activating
effect on NF-κB in THP1-MD2-CD14 cells. The HMO 3-FL only had a
statistically significant effect at a concentration of 2mg/mL
(p < 0.05). 6′-SL did not show NF-κB activating effects. For LNT2, 0.5,
1, and 2mg/mL all showed significantly NF-κB activating effects
(0.5 mg/mL, p < 0.05; 1mg/mL, p < 0.01; 2mg/mL, p < 0.001).
The effects were dose dependent. LNnT had no effect on NF-κB acti-
vation.
To determine TLR dependency, THP1-MD2-CD14 cells were in-
cubated with HMOs after inhibition of MyD88 with the MyD88 in-
hibitor Pepinh-MYD. The efficacy of the MyD88 inhibitor Pepinh-MYD
was confirmed on LPS stimulated THP1-MD2-CD14 cells, the effect of
LPS was significantly inhibited by Pepinh-MYD (p < 0.0001, Fig. 1B).
As shown in Fig. 1B, MyD88 inhibition blocked 3-FL activation de-
monstrating TLR dependency of this activation. The LNT2 induced ac-
tivation was partially TLR dependent as some activation was still ob-
served after MyD88 inhibition. Inhibition was dependent on the LNT2
concentration. At 0.5mg/mL LNT2, the TLR activation was completely
blocked (Fig. 1B), at 1 and 2mg/mL, the response was strongly but not
completely blocked (Fig. 1B). Although the remaining activations of 1
and 2mg/mL LNT2 were still statistically significantly higher than
medium control, the response was 6.4 fold and 10.4 fold decreased,
demonstrating the response is mainly but not completely TLR depen-
dent (1mg/mL LNT2, p < 0.001; 2mg/mL LNT2, p < 0.01).
Fig. 1. NF-κB/AP-1 activation in THP1-MD2-CD14 reporter cell and THP1-MD2-CD14 reporter cell with MyD88 inhibitor Pepinh-MYD after stimulation with HMOs.
2′-FL, 3-FL, 6′-SL, LNT2, and LNnT were tested at 0.5, 1, and 2mg/mL, culture medium served as negative control. A: THP1-MD2-CD14 reporter cell; B: THP1-MD2-
CD14 reporter cells with MyD88 inhibitor Pepinh-MYD. Data are presented as mean ± SD. Significant differences compared to the negative control were determined
by using Kruskal-Wallis test followed by the Dunn’s test and indicated by #,*p < 0.05; ##, **p < 0.01; ###, ***p < 0.001; ####, ****p < 0.0001(* vs control;
# vs LPS).
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3.2. HMO’s effects on individual TLRs
The results from the THP1-MD2-CD14 cell studies showed that 3FL
and LNT2 can activate NF-κB through TLR pathways. In order to in-
vestigate which specific TLRs are involved, HEK cells expressing TLR2,
TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9 were used. We include all
four HMOs and its acid hydrolysate LNT2 and test for both activating
and inhibiting effects to exclude any possible effects of the individual
HMOs on TLR.
To study possible activating effects, 0.5, 1, or 2mg/mL of 2′-FL, 3-
FL, 6′-SL, LNT2, and LNnT were added to the cells. The results of the
activating effects of 2′-FL, 6′-SL, and LNnT on the individual TLRs are
shown in Figs. S2, S3, and S4, respectively. The results corroborate the
observation in THP1 cells and show that these HMOs had no activating
effects on any of the TLRs tested. Only 3-FL and LNT2 had activation
effects which results are shown in Figs. 2 and 3. The HMO 3-FL only
activated TLR2 (Fig. 2). The activating effects were dose dependent. At
a concentration of 0.5, 1, and 2mg/mL the 3-FL induced an 8.9
(p < 0.05), 14.1 (p < 0.001), and 20.9 (p < 0.0001) fold increase of
NF-κB activation respectively compared to control.
LNT2 statistically significantly activated all the TLRs in a dose-de-
pendent way (Fig. 3). LNT2 at 0.5 mg/mL activated only TLR2, 5, and 9
(TLR2 and 5: p < 0.0001; TLR9: p < 0.05); LNT2 at 1mg/mL acti-
vated TLR2, 3, 5, 8, 9 (TLR2, 5, and 9: p < 0.001; TLR3, 8: p < 0.05);
LNT2 at 2mg/mL activated all the TLRs (TLR2, 5, and 9: p < 0.001;
TLR3, 4, 7, and 8: p < 0.01). It showed a different activation pattern
on different TLRs, but for all the TLRs, the activation effect was in-
creasing with increasing concentrations.
To exclude this we performed additional controls but also our data
indicate it can not be explained by endotoxin only. First, we added the
LNT2 to the culture medium after sterile 0.2 μm filtration which re-
moves bacteria and sterilize the solutions. Subsequently the LAL assay
indicate that the 2mg/mL LNT2 showed high endotoxin levels (1.7 EU/
mL) while 0.5mg/mL 0.2 μm filtration LNT2 contained very low
endotoxin levels (< 0.1 EU/mL) (Fig. S1). This 0.5 mg/mL LNT2 with
virtually no endotoxin still induced activation on TLR2, 5, and 9 in-
dicating the LNT2 is responsible for TLR activation. However to further
exclude that the TLR4 activation of the LNT2 was caused by possible
contamination with LPS, we added 100 µg/mL polymyxin B to the LNT2
to capture any LPS present in the samples (Fig. S5). The effectivity of
polymyxin B was confirmed on TLR4 reporter cells, as a complete
blockade of the LPS signal was observed (Fig. S5A). Polymyxin B re-
duced the LNT2 induced TLR4 activation but the remaining activation
was still profound and statistically significantly higher than medium
control (Fig. S5B). Also as TLR2 and 4, i.e. the predominant receptors
for endotoxins, were not more strongly activated than other receptors
we conclude that the observed effects were predominantly caused by
the LNT2 itself.
We also investigated such ability of 2′-FL, 3-FL, 6′-SL, LNT2, and
LNnT. This was done by incubating HEK-TLR cells with 0.5, 1, and
2mg/mL HMOs and relevant TLR agonist. We found that 2′-FL, 6′-SL
and LNnT had some inhibiting effects on TLR signaling as will be spe-
cified in more detail below. TLR2, 3, 4, and 9 was not inhibited by any
of the tested HMOs. The full range of outcomes is shown in Fig. S6.
Fig. 4 presents only the TLRs which were inhibited by HMOs. As shown
in Fig. 4A, 2′-FL, 3-FL, 6′-SL, and LNnT suppressed TLR5 activation only
at the lowest concentration HMOs tested (0.5mg/mL, all p < 0.05). No
inhibition was observed at concentrations of 1 and 2mg/mL. Such an
inverse dose dependent effect was observed for TLR7 suppression as
well. Both at 0.5 mg/mL of 2′-FL (p < 0.05), 3-FL (p < 0.01), 6′-SL
(p < 0.01) and 1mg/mL of 2′-FL (p < 0.05), 3-FL (p < 0.05), 6′-SL
(p < 0.01), and LNnT (p < 0.05) inhibition of CL264 induced TLR7
activation was observed, while none of the HMOs showed significant
effects on TLR7 inhibition at a concentration of 2mg/mL (Fig. 4B). For
TLR8 inhibition, different results were obtained, the inhibition effects
on TLR8 were enhanced with increasing concentrations. Only 1 and
2mg/mL 3-FL (both p < 0.01) showed significant inhibition of TLR8
activation, while 0.5mg/mL 3-FL showed a trend to suppress TLR8
Fig. 2. Activating effects of 3-FL on HEK reporter cells carrying individual TLRs. Cells were incubated with 3-FL at 0.5, 1, 2 mg/mL, culture medium served as
negative control. Data are presented as mean ± SD. Significant differences compared to the negative control were determined by using one-way ANOVA with Dunn’s
multiple comparison tests and indicated by * (p < 0.05), ** (p < 0.01), *** (p < 0.001) or by **** (p < 0.0001).
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activation to 82.2% (p=0.07, Fig. 4C). Also, we observed that 6′-SL
and LNT2 showed significant enhancing effects on TLR8 activation but
only at the highest concentration of 2mg/mL (p < 0.01). Interestingly,
6′-SL did not inhibit but augmented TLR8 activation in the presence of
the agonist (ssRNA40) at a concentration of 2mg/mL while it had no
activation effect as a single molecule on TLR8.
3.3. Induction of cytokine production in THP1 macrophages by LNT2
The above-mentioned activation and inhibition of TLRs by HMOs
and its acid hydrolysate LNT2 promoted us to test whether HMOs have
immunomodulatory effects on TLR carrying cells such as macrophages.
To this end, PMA-differentiated THP1 macrophages were stimulated
with 0.5, 1, and 2mg/mL HMOs for 24 h after which the concentrations
of the pro-inflammatory cytokine TNFα and the regulatory cytokine IL-
10 in the supernatant were measured.
As shown in Fig. 5, only LNT2 could significantly increase cytokine
production of TNFα and IL-10, and the effects were dose dependent.
LNT2 was able to induce high TNFα production in all tested con-
centrations (0.5 and 1mg/mL: p < 0.001; 2mg/mL: p < 0.0001),
while for IL-10, only 1 and 2mg/mL LNT2 could significantly increase
IL-10 production (1mg/mL, p < 0.05; 2mg/mL, p < 0.01). Incuba-
tion with 0.5 mg/mL LNT2 was not able to increase IL-10 production
significantly, but it did show a trend to inducing enhanced IL-10 pro-
duction by the macrophages (p=0.069).
3.4. Cytokine expression was NF-κB dependent in THP1 macrophages
In order to confirm the NF-κB dependency of cytokine expression
induced by LNT2, PMA-differentiated THP1 macrophages were stimu-
lated with 0.5, 1, and 2mg/mL LNT2 in the presence or absence of the
NF-κB inhibitor celastrol. As shown in Fig. 6, incubation with celastrol
inhibited production of TNFα and IL-10 induced by LNT2. TNFα
produced by the THP1 macrophages after incubating with 0.5mg/mL
(p < 0.05), 1 mg/mL (p < 0.001) and 2mg/mL (p < 0.01) LNT2 was
significantly decreased by celastrol. IL-10 production induced by 1 and
2mg/mL LNT2 (p < 0.05) was also inhibited by celastrol. Celastrol
also showed a trend of decreasing the IL-10 production induced by
0.5 mg/mL LNT2 (p=0.075). Overall, the data above showed the
TNFα and IL-10 production induced by LNT2 was NF-κB dependent.
4. Discussion
The immune effects of HMOs through TLRs have been previously
described in vitro (Asakuma et al., 2010; He et al., 2014; Thomas et al.,
2014), and in vivo (Kurakevich et al., 2013), however, the effects of
different HMOs on individual TLRs are to the best of our knowledge not
studied before. Here, we show that the immunomodulatory effects via
TLRs of 2′-FL, 3-FL, 6′-SL, LNT2, and LNnT, is HMO structure-depen-
dent. While 3-FL and LNT2 had TLR stimulating effects, the 2′-FL, 6′-SL,
and LNnT were inhibiting TLR5 and 7, besides that, 3-FL also showed
inhibition effects on TLR5, 7, and 8.
3-FL showed direct stimulatory effects on TLR2 in a dose-dependent
way. Notably, 2′-FL and 3-FL have approximately the same molecular
composition. Sharing the same molecular composition, all carrying
lactose at their reducing end. 2′-FL and 3-FL only differ in the attach-
ment position of L-fucose (Fuc) residues on the lactose core region
(Table 1). This difference might, however, be responsible for the dif-
ference in binding capacity to TLRs. TLR2 can form a specific binding
pocket of equine TLR2/1 and TLR2/6 heterodimers (Botos, Segal, &
Davies, 2011; Irvine, Hopkins, Gangloff, & Bryant, 2013). Differences in
the structural makeup of Fuc on the backbone between 2′-FL and 3-FL
might be responsible for the different effects on TLR2 between the two
molecules and might make that only 3-FL can bind to the ligand posi-
tion and activate TLR2. It has been shown for other carbohydrates that
minor differences in structural makeup have a significant impact on the
Fig. 3. Activation effects of LNT2 on HEK reporter cells carrying individual TLRs. Cells were incubated with LNT2 at 0.5, 1, 2mg/mL, culture medium served as
negative control. Data are presented as mean ± SD. Significant differences compared to the negative control were determined by using one-way ANOVA with Dunn’s
multiple comparison tests and indicated by * (p < 0.05), ** (p < 0.01), *** (p < 0.001) or by **** (p < 0.0001).
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binding capacity to especially TLR2 (Sahasrabudhe et al., 2018).
Despite its TLR2 activating effect, direct stimulation of 3-FL on
THP1 macrophages did not induce any change in cytokine production.
It was recently shown that the final effects of food ingredients on NF-κB
regulation in THP1 macrophages dependent on the sum of activating
and inhibiting effects on TLRs (Kiewiet et al., 2017; Lépine & de Vos,
2018; Sahasrabudhe et al., 2018). In addition to activating TLR2, we
found that 3-FL inhibited TLR 5, 7, and 8 (Fig. 7A). As the net effects of
Fig. 4. Inhibitory effects of HMOs on (A) HEK-Blue hTLR5, (B) HEK-Blue hTLR7, and (C) HEK-Blue hTLR8.cells. Cells were incubated with 2′-FL, 3-FL, 6′-SL, LNT2,
and LNnT at 0.5, 1, 2mg/mL together with its relevant agonist. Data are presented as mean ± SD. Significant differences compared to the control (relevant agonist)
were determined by using two-way ANOVA and indicated by * (p < 0.05), ** (p < 0.01), *** (p < 0.001) or by **** (p < 0.0001).
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immune activation depend on the sum of activation and inhibition of
TLRs, the final effects of this combined effects on TLRs are probably
lack of activation of the macrophages. This is corroborated by the ob-
servation on THP1 cells (Fig. 1) in which modest overall stimulation of
THP1 cells was observed by 3-FL. Only at a concentration of 2mg/mL,
we observed a modest activation of 1.89 times fold-change of NF-κB.
Stimulating effects of LNT2 were observed on all TLRs tested
(Fig. 7B). To the best of our knowledge, direct activation effects of TLRs
by LNT2 have not been reported before. It might be argued that the
strong and broad LNT2 TLR activating effect was caused by endotoxins
in the samples. Our data indicate this activation cannot be solely ex-
plained by the positive signal in the LAL assay at 2mg/mL. At 0.5 mg/
mL LNT2, the LNT2 had very low endotoxin levels (< 0.1 EU/mL) (Fig.
S1) but still demonstrated TLR activation. Another experiment that
made us conclude that LNT2 itself is partly responsible for TLR4 acti-
vation is that polymyxin B, a potent LPS neutralizer reduced TLR4 ac-
tivation by LNT2 but LNT2 still showed TLR activation (Fig. S5B). As
the difference in the LAL assay did not reflect the only fourfold differ-
ence in concentration, we suspect that the 2mg/ml endotoxin value
might be a false positive signal. It has been reported before that some
LAL reactive glucans might result in the false positive signals in the LAL
assay (Roslansky & Novitsky, 1991), the large difference in LAL assay
outcome between the 0.5mg/mL and 2mg/mL might suggest a false
positive signal in our study as well.
The activating effects of LNT2 might be explained by its structural
composition that allows for interaction with N-terminal ectodomains
(ECDs) that are present on all TLRs. The ECDs are composed of ap-
proximately 16–28 of a motif known as the leucine-rich repeats (LRR).
Each LRR consists of 20–30 amino acids with the conserved motif
‘‘LxxLxLxxN” (Botos et al., 2011; Jin & Lee, 2008; Kumar, Kawai, &
Akira, 2009). All LRRs can form a loop structure, beginning with an
extended stretch that contains three residues in the β strand config-
uration (Bella, Hindle, McEwan, & Lovell, 2008). Different from other
tested samples, LNT2 has the above mentioned N-acetylglucosamine
(GlcNAc) end (Table 1), which plays a variety of roles on the cell sur-
face of bacteria (Camacho et al., 2017; Konopka, 2012). This GlcNAc
might interact with LRR, which is the conserved part of TLRs, resulting
in the activation of all TLRs we tested. The activating effects on in-
dividual TLRs were different, but the effect is enhanced as the con-
centration increases (Fig. 3). This suggests that the TLR interaction
effects are dose-dependent. The effects of LNT2 on direct immune sti-
mulation were confirmed by exposing THP1 macrophage to LNT2
which resulted in enhanced TNFα, and IL-10 production through the
NF-κB pathway (Fig. 7B).
We did not detect activating effects of 6′-SL on TLR2 and TLR4,
which differs from the observations of Asakuma (Asakuma et al., 2010).
Fig. 5. (A) TNFα and (B) IL-10 production by THP1 macrophages stimulated with 0.5, 1, and 2mg/mL HMOs. PMA-stimulated THP1 macrophages were treated with
2′-FL, 3-FL, 6′-SL, LNT2, and LNnT at 0.5, 1, 2 mg/mL or 1 µg/mL LPS (positive control) for 24 h. Untreated THP1 macrophages served as negative control. Data are
presented as mean ± SD. Significant differences compared to the negative control were determined by using Kruskal-Wallis test followed by the Dunn’s test and
indicated by * (p < 0.05), ** (p < 0.01), *** (p < 0.001) or by **** (p < 0.0001).
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Asakuma has suggested that 6′-SL has a direct effect on colonic epi-
thelial HT-29 cells and induces mRNA expression of TLR2 and TLR4
(Asakuma et al., 2010). TLR4 and to a lesser extent TLR2 are receptors
that are sensitive for endotoxins present in food components. It cannot
be excluded that possible contamination in the 6′-SL in the Asakuma
study has been responsible for the TLR2 and TLR4 activating effects and
explains the discrepancy between our findings and that of the Asakuma
study. In our study, we applied virtually endotoxin free 6′-SL (Figure
S1), which made us believe we can safely conclude that 6′-SL has no
TLR2 and TLR4 activating effects.
As it has been shown that TLRs can not only be activated but also be
inhibited by carbohydrates (Figueroa-Lozano et al., 2018; Kiewiet et al.,
2017; Sahasrabudhe et al., 2018), the inhibiting effects were tested as a
potential mechanism for immunomodulation. We observed that 3-FL
not only showed activation effects on TLR2 but also had inhibiting ef-
fects on TLR 5, 7, and 8. Also, 2′-FL, 6′-SL, and LNnT showed TLR in-
hibiting effects while no activating effects were found with these HMOs
(Fig. 7C). A few studies demonstrate that inhibition of TLR 5, 7, and 8
might be instrumental in managing inflammatory and autoimmune
diseases (Blohmke et al., 2008; Kuznik et al., 2011). As 2′-FL, 3-FL, 6′-
SL, and LNnT have these inhibitory effects, they might be ther-
apeutically applicable. To our surprise, the results indicated that the
inhibition effects on TLR5 and 7 were inversely dose-dependent. Low
concentrations of HMOs inhibited the activation effects on TLR5 and 7
induced by angonist, whereas high concentrations had no effects. The
inverse dose-dependent manner had been reported to be present for
other antagonists (Palmon et al., 2000; Tardy et al., 2015). For ex-
ample, low concentrations of basic fibroblast growth factor (bFGF)
enhanced collagen type I and depressed collagenase-1 expression,
whereas high bFGF concentrations had no inhibiting effects (Palmon
et al., 2000). To the best of our knowledge, this inversely dose-depen-
dent inhibition effects on TLRs have not been reported before. These
results suggested that 2′-FL, 3-FL, 6′-SL, and LNnT might be important
regulators of the TLR dependent NF-κB pathway.
Notably, 2mg/mL 6′-SL had a synergistic effect on ssRNA40 in-
duced TLR8 activation while this HMO had no effect as a single mo-
lecule on TLR8. TLR8 activation in contrast to activation of other TLRs
is a multistep process. TLR8 activation first requires the formation of an
apo TLR8 dimer after a proteolytic cleavage that subsequently induces a
conformational change of TLR8 upon ligand binding (Geyer, Pelka, &
Latz, 2015; Tanji et al., 2015, 2016; Yin, Fu, Li, & Wu, 2015). Upon
binding of ssRNA to the TLR8 binding site, an activated dimer is formed
with the uridine part of ssRNA in the receptor (Botos et al., 2011; Tanji
et al., 2015). This changes the ligand binding site and the distance
between the C-termini that might be responsible for binding of other
ligands such as 6′-SL (Geyer et al., 2015; Tanji et al., 2015). The C
termini in the agonist-bound TLR8 dimer are much closer to each other
than those in the inactivated-TLR8 dimer. The measured distances be-
tween the C termini in activated TLR8 was ∼30 Å which is smaller than
the ∼53 Å in the inactivated TLR8 dimers (Yin et al., 2015). This dif-
ference in the distance might explain the difference in binding and
activating capacity of 6′-SL between inactivated the form of TLR8 and
the activated TLR8 (Fig. 7D).
5. Conclusion
We demonstrate that the immunomodulatory effects of HMOs are
highly structure dependent. Different structures of HMOs showed dif-
ferent activation and inhibition effects on TLR signaling pathways. Our
data indicate that some specific HMOs, such as LNT2, are able to sti-
mulate immune activation. We also identified that TLR 5, 7, and 8,
which are involved in many pathologies, such as cystic fibrosis lung
disease and systemic lupus erythematosus (Blohmke et al., 2008;
Kuznik et al., 2011), were inhibited by some specific HMOs. Under-
standing how and which HMO modulate immunity, contributes to the
future design of HMO containing products with predictable beneficial
effects in specific target groups. Overall, our data not only contribute to
a better understanding of how HMOs can have immunomodulatory
effects, it also provides a new way to manage diseases, like systemic
lupus erythematosus and rheumatoid arthritis (Karlsson, Sun, Rao,
Venable, & Thurmond, 2008), with nutritional supply.
6. Ethics statements
No human suject and animal experiments in the research.
Author contributions
L.C., M.B.G.K., and P.d.V conceived and designed the experiments.
L.C. performed the experiments. L.C. analyzed data. A.G. and A.N.
Fig. 6. (A) TNFα and (B) IL-10 production by THP1 macrophages stimulated with 0.5, 1, and 2mg/mL LNT2 in the presence or absence of celastrol. PMA-stimulated
THP1 macrophages were treated with LNT2 at 0.5, 1, 2mg/mL or 1 µg/mL LPS (positive control) in the presence or absence of NF-κB inhibitors celastrol for 24 h.
Untreated THP1 macrophages served as negative control. Data are presented as mean ± SD. Significant differences were determined by using unpaired t-test and
indicated by * (p < 0.05), ** (p < 0.01), *** (p < 0.001) or by **** (p < 0.0001).
L. Cheng, et al. Journal of Functional Foods 59 (2019) 174–184
182
provided the tested samples and joined the discussion. L.C., M.B.G.K.,
and P.d.V. wrote the paper.
Funding
The project was financially supported by the China Scholarship
Council [grant number 201505990304] and Friesland Campina. This
research was performed within the framework of the Sino-Dutch
Doctoral Program on Sustainable Dairy coordinated by the
Carbohydrate Competence Center (CCC, www.cccresearch.nl).
Declaration of Competing Interest
The authors have declared no conflict of interest.
Appendix A. Supplementary material
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jff.2019.05.023.
References
Abreu, M. T. (2010). Toll-like receptor signalling in the intestinal epithelium: How bac-
terial recognition shapes intestinal function. Nature Reviews Immunology, 10(2),
131–144. https://doi.org/10.1038/nri2707.
Asakuma, S., Hatakeyama, E., Urashima, T., Yoshida, E., Katayama, T., Yamamoto, K., ...
Kitaoka, M. (2011). Physiology of consumption of human milk oligosaccharides by
infant gut-associated bifidobacteria. Journal of Biological Chemistry, 286(40),
34583–34592. https://doi.org/10.1074/jbc.M111.248138.
Asakuma, S., Yokoyama, T., Kimura, K., Watanabe, Y., Nakamura, T., Fukuda, K., &
Urashima, T. (2010). Effect of human milk oligosaccharides on messenger ribonucleic
acid expression of toll-like receptor 2 and 4, and of MD2 in the intestinal cell line HT-
29. Journal of Applied Glycoscience, 575(3), 177–183. https://doi.org/10.5458/jag.57.
177.
Ayechu-Muruzabal, V., van Stigt, A. H., Mank, M., Willemsen, L. E. M., Stahl, B., Garssen,
J., & van’t Land, B. (2018). Diversity of human milk oligosaccharides and effects on
early life immune development. Frontiers in Pediatrics, 6, 239. https://doi.org/10.
3389/fped.2018.00239.
Belfort, M. B. (2018). Human milk and preterm infant brain development. Breastfeeding
Medicine, 13(S1), S-23–S-25. https://doi.org/10.1089/bfm.2018.29079.mbb.
Bella, J., Hindle, K. L., McEwan, P. A., & Lovell, S. C. (2008). The leucine-rich repeat
structure. Cellular and Molecular Life Sciences, 65(15), 2307–2333. https://doi.org/10.
1007/s00018-008-8019-0.
Bidart, G. N., Rodríguez-Díaz, J., & Yebra, M. J. (2016). The extracellular wall-bound β-N-
Fig. 7. Schematic representation of the immunomodulatory effects of tested HMOs. A–C: Immune regulation effects of HMOs through TLR signal pathway; D:
Proposed mechanism of activation effect of 6′-SL on ssRNA40 activated TLR8. : activation effect; : inhibition effect; : no significant effect.
L. Cheng, et al. Journal of Functional Foods 59 (2019) 174–184
183
acetylglucosaminidase from Lactobacillus casei is involved in the metabolism of the
human milk oligosaccharide lacto-N-triose. Applied and Environmental Microbiology,
82(2), 570–577. https://doi.org/10.1128/AEM.02888-15.
Blohmke, C. J., Victor, R. E., Hirschfeld, A. F., Elias, I. M., Hancock, D. G., Lane, C. R., ...
Turvey, S. E. (2008). Innate immunity mediated by TLR5 as a novel anti in-
flammatory target for cystic fibrosis lung disease. Journal of Immunology, 180(11),
7764–7773. https://doi.org/10.4049/JIMMUNOL.180.11.7764.
Bode, L. (2012). Human milk oligosaccharides: Every baby needs a sugar mama.
Glycobiology, 22(9), 1147–1162. https://doi.org/10.1093/glycob/cws074.
Bode, L., Kunz, C., Muhly-Reinholz, M., Mayer, K., Seeger, W., & Rudloff, S. (2004).
Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by
human milk oligosaccharides. Thrombosis and Haemostasis, 92(12), 1402–1410.
https://doi.org/10.1160/TH04-01-0055.
Botos, I., Segal, D. M., & Davies, D. R. (2011). The structural biology of toll-like receptors.
Structure, 19(4), 447–459. https://doi.org/10.1016/J.STR.2011.02.004.
Buescher, E. S. (2001). Anti-inflammatory characteristics of human milk. In D. S.
Newburg (Ed.). Bioactive components of human milk (pp. 207–222). Boston, MA:
Springer. https://doi.org/10.1007/978-1-4615-1371-1_27.
Camacho, E., Chrissian, C., Cordero, R. J. B., Liporagi-Lopes, L., Stark, R. E., & Casadevall,
A. (2017). N-acetylglucosamine affects Cryptococcus neoformans cell-wall composi-
tion and melanin architecture. Microbiology, 163(11), 1540–1556. https://doi.org/
10.1099/mic.0.000552.
Chanput, W., Mes, J. J., & Wichers, H. J. (2014). THP-1 cell line: An in vitro cell model for
immune modulation approach. International Immunopharmacology, 23(1), 37–45.
https://doi.org/10.1016/j.intimp.2014.08.002.
Deo, V. K., & Park, E. Y. (2006). Multiple co-transfection and co-expression of human β-
1,3-N-acetylglucosaminyltransferase with human calreticulin chaperone cDNA in a
single step in insect cells. Biotechnology and Applied Biochemistry, 43(3), 129. https://
doi.org/10.1042/ba20050157.
Figueroa-Lozano, S., Valk-Weeber, R. L., van Leeuwen, S. S., Dijkhuizen, L., & de Vos, P.
(2018). Dietary N-glycans from bovine lactoferrin and TLR modulation. Molecular
Nutrition & Food Research, 62(2), 1700389. https://doi.org/10.1002/mnfr.
201700389.
Geyer, M., Pelka, K., & Latz, E. (2015). Synergistic activation of Toll-like receptor 8 by
two RNA degradation products. Nature Structural & Molecular Biology, 22(2), 99–101.
https://doi.org/10.1038/nsmb.2967.
Gnoth, M. J., Kunz, C., Kinne-Saffran, E., & Rudloff, S. (2000). Human milk oligo-
saccharides are minimally digested in vitro. The Journal of Nutrition, 130(12),
3014–3020. https://doi.org/10.1093/jn/130.12.3014.
He, Y., Lawlor, N. T., & Newburg, D. S. (2016). Human milk components modulate toll-
like receptor-mediated inflammation. Advances in Nutrition, 7(1), 102–111. https://
doi.org/10.3945/an.115.010090.
He, Y., Liu, S., Kling, D. E., Leone, S., Lawlor, N. T., Huang, Y., ... Newburg, D. S. (2016).
The human milk oligosaccharide 2’-fucosyllactose modulates CD14 expression in
human enterocytes, thereby attenuating LPS-induced inflammation. Gut, 65(1),
33–46. https://doi.org/10.1136/gutjnl-2014-307544.
He, Y., Liu, S., Leone, S., & Newburg, D. S. (2014). Human colostrum oligosaccharides
modulate major immunologic pathways of immature human intestine. Mucosal
Immunology, 7(6), 1326–1339. https://doi.org/10.1038/mi.2014.20.
Irvine, K., Hopkins, L., Gangloff, M., & Bryant, C. (2013). The molecular basis for re-
cognition of bacterial ligands at equine TLR2, TLR1 and TLR6. Veterinary Research,
44(1), 50. https://doi.org/10.1186/1297-9716-44-50.
Jantscher-Krenn, E., Zherebtsov, M., Nissan, C., Goth, K., Guner, Y. S., Naidu, N., ... Bode,
L. (2012). The human milk oligosaccharide disialyllacto-N-tetraose prevents necro-
tising enterocolitis in neonatal rats. Gut, 61(10), 1417–1425. https://doi.org/10.
1136/gutjnl-2011-301404.
Jin, M. S., & Lee, J.-O. (2008). Structures of the toll-like receptor family and its ligand
complexes. Immunity, 29(2), 182–191. https://doi.org/10.1016/J.IMMUNI.2008.07.
007.
Karlsson, L., Sun, S., Rao, N., Venable, J., & Thurmond, R. (2008). TLR7/9 antagonists as
therapeutics for immune-mediated inflammatory disorders. Inflammation & Allergy-
Drug Targets, 6(4), 223–235. https://doi.org/10.2174/187152807783334300.
Kawai, T., & Akira, S. (2010). The role of pattern-recognition receptors in innate im-
munity: Update on toll-like receptors. Nature Immunology, 11(5), 373–384. https://
doi.org/10.1038/ni.1863.
Kiewiet, M. B. G., Dekkers, R., Gros, M., van Neerven, R. J. J., Groeneveld, A., de Vos, P.,
& Faas, M. M. (2017). Toll-like receptor mediated activation is possibly involved in
immunoregulating properties of cow’s milk hydrolysates. PLOS ONE, 12(6),
e0178191. https://doi.org/10.1371/journal.pone.0178191.
Klement, E., Cohen, R. V., Boxman, J., Joseph, A., & Reif, S. (2004). Breastfeeding and
risk of inflammatory bowel disease: A systematic review with meta-analysis. The
American Journal of Clinical Nutrition, 80(5), 1342–1352. https://doi.org/10.1093/
ajcn/80.5.1342.
Konopka, J. B. (2012). N-acetylglucosamine functions in cell signaling. Scientifica, 2012,
1–15. https://doi.org/10.6064/2012/489208.
Kumar, H., Kawai, T., & Akira, S. (2009). Toll-like receptors and innate immunity.
Biochemical and Biophysical Research Communications, 388(4), 621–625. https://doi.
org/10.1016/J.BBRC.2009.08.062.
Kunz, C., Rudloff, S., Baie, W., Klein, N., & St, S. (2000). Oligosaccharides in human milk:
Structural, functional, and metabolic aspects. Annual Review Nutrition, 699–722.
https://doi.org/10.1146/annurev.nutr.20.1.699.
Kurakevich, E., Hennet, T., Hausmann, M., Rogler, G., & Borsig, L. (2013). Milk oligo-
saccharide sialyl(2,3)lactose activates intestinal CD11c+ cells through TLR4.
Proceedings of the National Academy of Sciences, 110(43), 17444–17449. https://doi.
org/10.1073/pnas.1306322110.
Kuznik, A., Bencina, M., Svajger, U., Jeras, M., Rozman, B., & Jerala, R. (2011).
Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquino-
lines. The Journal of Immunology, 186(8), 4794–4804. https://doi.org/10.4049/
jimmunol.1000702.
Ladomenou, F., Moschandreas, J., Kafatos, A., Tselentis, Y., & Galanakis, E. (2010).
Protective effect of exclusive breastfeeding against infections during infancy: A
prospective study. Archives of Disease in Childhood, 95(12), 1004–1008. https://doi.
org/10.1136/adc.2009.169912.
Lane, J. A., O’Callaghan, J., Carrington, S. D., & Hickey, R. M. (2013). Transcriptional
response of HT-29 intestinal epithelial cells to human and bovine milk oligo-
saccharides. British Journal of Nutrition, 110(12), 2127–2137. https://doi.org/10.
1017/S0007114513001591.
Lépine, A., & de Vos, P. (2018). Synbiotic effects of the dietary fiber long-chain inulin and
probiotic lactobacillus acidophilus W37 can be caused by direct, synergistic stimu-
lation of immune toll-like receptors and dendritic cells. Molecular Nutrition and Food
Research, 62(15), e1800251. https://doi.org/10.1002/mnfr.201800251.
Medzhitov, R. (2001). Toll-like receptors and innate immunity. Nature Reviews
Immunology, 1(2), 135–145. https://doi.org/10.1038/35100529.
Morrow, A. L., Ruiz-Palacios, G. M., Altaye, M., Jiang, X., Lourdes Guerrero, M., Meinzen-
Derr, J. K., ... Newburg, D. S. (2004). Human milk oligosaccharides are associated
with protection against diarrhea in breast-fed infants. Journal of Pediatrics, 145(3),
297–303. https://doi.org/10.1016/j.jpeds.2004.04.054.
Palmon, A., Roos, H., Edel, J., Zax, B., Savion, N., Grosskop, A., & Pitaru, S. (2000).
Inverse dose- and time-dependent effect of basic fibroblast growth factor on the gene
expression of collagen type I and matrix metalloproteinase-1 by periodontal ligament
cells in culture. Journal of Periodontology, 71(6), 974–980. https://doi.org/10.1902/
jop.2000.71.6.974.
Petherick, A. (2010). Development: Mother’s milk: A rich opportunity. Nature, 468(7327),
S5–S7. https://doi.org/10.1038/468s5a.
Ren, C., Zhang, Q., De Haan, B. J., Zhang, H., Faas, M. M., & De Vos, P. (2016).
Identification of TLR2/TLR6 signalling lactic acid bacteria for supporting immune
regulation. Scientific Reports, 6(1), 2045–2322. https://doi.org/10.1038/srep34561.
Roslansky, P. F., & Novitsky, T. J. (1991). Sensitivity of Limulus amebocyte lysate (LAL)
to LAL-reactive glucans. Journal of Clinical Microbiology, 29(11), 2477–2483
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1774252.
Sahasrabudhe, N. M., Beukema, M., Tian, L., Troost, B., Scholte, J., Bruininx, E., ... de Vos,
P. (2018). Dietary fiber pectin directly blocks toll-like receptor 2–1 and prevents
doxorubicin-induced ileitis. Frontiers in Immunology, 9(MAR), 383. https://doi.org/
10.3389/fimmu.2018.00383.
Sahasrabudhe, N. M., Schols, H. A., Faas, M. M., & de Vos, P. (2016). Arabinoxylan ac-
tivates Dectin-1 and modulates particulate β-glucan-induced Dectin-1 activation.
Molecular Nutrition & Food Research, 60(2), 458–467. https://doi.org/10.1002/mnfr.
201500582.
Smilowitz, J. T., Lebrilla, C. B., Mills, D. A., German, J. B., & Freeman, S. L. (2014). Breast
milk oligosaccharides: Structure-function relationships in the neonate. Annual Review
of Nutrition, 34(1), 143–169. https://doi.org/10.1146/annurev-nutr-071813-105721.
Tanji, H., Ohto, U., Motoi, Y., Shibata, T., Miyake, K., & Shimizu, T. (2016).
Autoinhibition and relief mechanism by the proteolytic processing of Toll-like re-
ceptor 8. Proceedings of the National Academy of Sciences of the United States of America,
113(11), 3012–3017. https://doi.org/10.1073/pnas.1516000113.
Tanji, H., Ohto, U., Shibata, T., Taoka, M., Yamauchi, Y., Isobe, T., ... Shimizu, T. (2015).
Toll-like receptor 8 senses degradation products of single-stranded RNA. Nature
Structural and Molecular Biology, 22(2), 109–116. https://doi.org/10.1038/nsmb.
2943.
Tardy, C., Goffinet, M., Boubekeur, N., Cholez, G., Ackermann, R., Sy, G., ... Baron, R.
(2015). HDL and CER-001 inverse-dose dependent inhibition of atherosclerotic
plaque formation in apoE-/- mice: evidence of ABCA1 down-regulation. PLOS ONE,
10(9), e0137584. https://doi.org/10.1371/journal.pone.0137584.
Thomas, P. G., Carter, M. R., Atochina, O., Da’Dara, A. A., Piskorska, D., McGuire, E., &
Harn, D. A. (2014). Maturation of dendritic cell 2 phenotype by a helminth glycan
uses a toll-like receptor 4-dependent mechanism. The Journal of Immunology, 171(11),
5837–5841. https://doi.org/10.4049/jimmunol.171.11.5837.
Velupillai, P., & Harn, D. A. (1994). Oligosaccharide-specific induction of interleukin 10
production by B220+ cells from schistosome-infected mice: A mechanism for reg-
ulation of CD4+ T-cell subsets. Proceedings of the National Academy of Sciences, 91(1),
18–22. https://doi.org/10.1073/pnas.91.1.18.
Vogt, L., Ramasamy, U., Meyer, D., Pullens, G., Venema, K., Faas, M. M., ... de Vos, P.
(2013). Immune modulation by different types of β2→1-fructans is toll-like receptor
dependent. PLoS ONE, 8(7), e68367. https://doi.org/10.1371/journal.pone.
0068367.
Vos, A. P., M’rabet, L., Stahl, B., Boehm, G., Garssen, J., & Askenase, P. W. (2007).
Immune-modulatory effects and potential working mechanisms of orally applied
nondigestible carbohydrates. Critical Reviews TM in Immunology, 27(2), 97–140.
https://doi.org/10.1615/critrevimmunol.v27.i2.10.
Walker, A. (2010). Breast milk as the gold standard for protective nutrients. The Journal of
Pediatrics, 156(2), S3–S7. https://doi.org/10.1016/J.JPEDS.2009.11.021.
Wang, B. (2009). Sialic acid is an essential nutrient for brain development and cognition.
Annual Review of Nutrition, 29(1), 177–222. https://doi.org/10.1146/annurev.nutr.
28.061807.155515.
Yin, Q., Fu, T.-M., Li, J., & Wu, H. (2015). Structural biology of innate immunity. Annual
Review of Immunology, 33(1), 393–416. https://doi.org/10.1146/annurev-immunol-
032414-112258.
L. Cheng, et al. Journal of Functional Foods 59 (2019) 174–184
184
